Clinical Trial Update: Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing lenvatinib plus selective internal radiation therapy (SIRT) versus lenvatinib alone in patients with TACE-refractory hepatocellular ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: RECRUITING